Google
Trusted Resources: News & Events
Latest announcements and gatherings
First systemic evidence for safety of tPA in stroke patients with sickle cell disease
In the largest report on acute stroke in sickle cell disease to date, researchers at the Medical University of South Carolina and elsewhere provide the first systemic evidence for the safe use of tPA in stroke patients with sickle cell disease.
Adult patients with sickle cell disease (SCD) who experience a stroke caused by a clot (i.e., ischemic strokes or IS) can be treated safely with tissue plasminogen activator (tPA) if they qualify, report investigators at the Medical University of South Carolina (MUSC) and elsewhere in the March 2017 issue of Stroke.
+myBinderRelated Content
-
The psychosocial impact of leg ulcers in patients with sickle cell disease: I don’t want them to know my littl...BACKGROUND: Sickle cell disease (SCD) i...
-
What is a bone marrow stem cell transplant?http://www.sicklecelltransplantconsortiu...
-
Development and Feasibility Testing of the Comfort Ability Program for Sickle Cell Pain: A Patient-Informed, Video-B...Objective: Even with optimized medical...
-
Hydroxyurea improves lung function in children with sickle cell diseaseFor the first time, researchers were abl...
-
Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Ga...Acetylon Pharmaceuticals, Inc., the lead...
-
Fighting Through Our Pain TV With Thomas J. Harrington MDhttps://www.youtube.com/watch?time_conti...
-
New treatment plan leads to better pain control for acute sickle cell crisisThere’s new hope for the 70,000 to 80,...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.